home / stock / gern / gern short
Short Information | Geron Corporation (NASDAQ:GERN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 28,526,319 |
Total Actual Volume | 181,273,232 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,426,316 |
Average Short Percentage | 16.19% |
Is there a GERN Short Squeeze or Breakout about to happen?
See the GERN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-25-2024 | $4.29 | $4.29 | $4.395 | $4.2 | 7,450,891 | 1,702,272 | 22.85% |
07-24-2024 | $4.25 | $4.29 | $4.51 | $4.2 | 19,515,857 | 5,696,990 | 29.19% |
07-23-2024 | $4.68 | $4.62 | $4.7 | $4.58 | 10,798,641 | 1,444,182 | 13.37% |
07-22-2024 | $4.66 | $4.68 | $4.74 | $4.6025 | 5,412,233 | 726,731 | 13.43% |
07-19-2024 | $4.685 | $4.6 | $4.765 | $4.59 | 4,162,510 | 641,904 | 15.42% |
07-18-2024 | $4.73 | $4.67 | $4.86 | $4.62 | 4,504,187 | 672,688 | 14.93% |
07-17-2024 | $4.91 | $4.76 | $4.94 | $4.72 | 12,765,302 | 1,921,310 | 15.05% |
07-16-2024 | $4.905 | $4.99 | $5.06 | $4.892 | 11,805,259 | 1,285,621 | 10.89% |
07-15-2024 | $4.69 | $4.9 | $4.91 | $4.65 | 7,522,404 | 1,044,352 | 13.88% |
07-12-2024 | $4.84 | $4.71 | $4.85 | $4.53 | 9,218,853 | 1,040,882 | 11.29% |
07-11-2024 | $4.59 | $4.76 | $4.92 | $4.59 | 15,435,221 | 1,289,283 | 8.35% |
07-10-2024 | $4.55 | $4.6 | $4.64 | $4.54 | 8,134,078 | 809,668 | 9.95% |
07-09-2024 | $4.51 | $4.58 | $4.64 | $4.51 | 7,537,859 | 1,629,549 | 21.62% |
07-08-2024 | $4.55 | $4.53 | $4.66 | $4.48 | 8,940,613 | 1,547,805 | 17.31% |
07-05-2024 | $4.32 | $4.53 | $4.545 | $4.32 | 5,499,669 | 1,245,230 | 22.64% |
07-03-2024 | $4.2 | $4.36 | $4.41 | $4.2 | 3,225,337 | 456,881 | 14.17% |
07-02-2024 | $4.34 | $4.17 | $4.37 | $4.16 | 6,077,503 | 1,096,304 | 18.04% |
07-01-2024 | $4.24 | $4.34 | $4.485 | $4.24 | 8,007,660 | 1,757,257 | 21.94% |
06-28-2024 | $4.48 | $4.24 | $4.48 | $4.18 | 19,541,278 | 1,169,629 | 5.99% |
06-27-2024 | $4.43 | $4.44 | $4.5 | $4.355 | 5,717,877 | 1,347,781 | 23.57% |
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...